Abstract
Background and Objective: Delayed recovery of platelets can be found in recipients of related donor haploidentical haematopoietic stem cell transplantation (HSCT). The objective of this study was to evaluate the safety of recombinant human thrombopoietin (rhTPO) administration prior to engraftment in patients who received related donor haploidentical HSCT.
Methods: Nineteen patients with haematological malignancies received rhTPO prior to platelet engraftment after related donor haploidentical HSCT. Safety and tolerability levels together with the influence of rhTPO on the outcome of transplantation were evaluated.
Results: Slight elevations in ALT and/or AST were observed in five patients; in two other patients, bilirubin levels increased slightly. No significant changes in routine examination findings and no allergic reactions were observed during the study period. Eighteen patients achieved platelet engraftment at a median of 16 (range 11–34) days. The cumulative ± SD incidence of acute graft-versus-host disease (GVHD) grade 1–4 at +100 days was 68.4 ± 10.7%, and that of chronic GVHD at 3 years was 24.7 ± 10.7%. Nine (47.4%) patients survived free of relapse, with a median follow-up of 1631 (1550–1734) days after transplantation.
Conclusion: Early administration of rhTPO prior to engraftment was safe and well tolerated in patients receiving related donor haploidentical HSCT.
This is a preview of subscription content, log in via an institution to check access.
References
Chen J, Herceg-Harjacek L, Groopman JE, et al. Regulation of platelet activation in vitro by the c-Mpl ligand, thrombopoietin. Blood 1995; 86: 4054–62
Basser RL, Rasko JE, Clarke K, et al. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet 1996; 348: 1279–81
Nash RA, Gooley T, Davis C, et al. The problem of thrombocytopenia after hematopoietic stem cell transplantation. Stem Cells 1996; 14Suppl. 1: 261–73
Chang YJ, Xu LP, Liu DH, et al. Platelet engraftment in patients with hematologic malignancies following unmanipulated haploidentical blood and marrow transplantation: effects of CD34+ cell dose and disease status. Biol Blood Marrow Transplant 2009; 15: 632–8
Basser RL, Rasko JE, Clarke K, et al. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood 1997; 89: 3118–28
Wolff SN, Herzig R, Lynch J, et al. Recombinant human thrombopoietin (rhTPO) after autologous bone marrow transplantation: a phase I pharmacokinetic and pharmacodynamic study. Bone Marrow Transplant 2001; 27: 261–8
Nash RA, Kurzrock R, Dipersio J, et al. A phase I trial of recombinant human thrombopoietin in patients with delayed platelets recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2000; 6: 25–34
Huang XJ, Liu DH, Liu KY, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematologic malignancies. Bone Marrow Transplant 2006; 38: 291–7
Huang XJ, Liu DH, Liu KY, et al. Treatment of acute leukaemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood and Marrow Transplant 2009; 15Suppl. 1: 91–4
Anasetti C, Rybka W, Sullivan KM, et al. Graft-v-host disease is associated with autoimmune-like thrombocytopenia. Blood 1989; 73: 1054–8
Rabinowe SN, Soiffer RJ, Tarbell NJ, et al. Hemolyticuremic syndrome following bone marrow transplantation in adults for hematologic malignancies. Blood 1991; 77: 1837–44
Klumpp TR, Block CC, Caligiuri MA, et al. Immunemediated cytopenia following bone marrow transplantation: case reports and review of the literature. Medicine 1992; 71: 73–83
Ulich TR, del Castillo J, Yin S, et al. Megakaryocyte growth and development factor ameliorates carboplatin-induced thrombocytopenia in mice. Blood 1995; 86: 971–6
Molineux G, Hartley CA, McElroy P, et al. Megakaryocyte growth and development factor stimulates enhanced platelets recovery in mice after bone marrow transplantation. Blood 1996 15; 88: 509–14
Neelis KJ, Hartong SC, Egeland T, et al. The efficacy of single-dose administration of thrombopoietin with coad-ministration of either granulocyte/macrophage or granulocyte colony-stimulating factor in myelosuppressed rhesus monkeys. Blood 1997; 90: 2565–73
Fanucchi M, Glaspy J, Crawford J, et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelets counts after chemotherapy for lung cancer. N Engl J Med 1997; 336: 404–9
Acknowledgements
No sources of funding were used to assist in the conduct of this study or the preparation of this article. The authors have no conflicts of interest that are directly relevant to the content of this study. D.-H. Liu performed the research and analysed and interpreted the data and drafted the manuscript. X.-J. Huang was involved in the study conception and design. All of the remaining authors were involved in the study design and patient treatment. The authors thank www.journalexperts.com for their assistance in revising the manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Liu, DH., Huang, XJ., Liu, KY. et al. Safety of Recombinant Human Thrombopoietin in Adults after Related Donor Haploidentical Haematopoietic Stem Cell Transplantation. Clin. Drug Investig. 31, 135–141 (2011). https://doi.org/10.1007/BF03256939
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03256939